Gene promoter methylation has been reported in gastric cancer (GC). However, the potential
applications of blood-based gene promoter methylation as a noninvasive biomarker for GC …

Aberrant promoter methylation and subsequent silencing of cancer-related genes has been
recognized as an important pathway involved in gastric carcinogenesis. In fact, several …

Most cases of gastric cancer (GC) are not diagnosed at early stage which can be curable, so
it is necessary to identify effective biomarkers for its diagnosis and pre‐warning. We have …

Promoter methylation acts as an important alternative to genetic alterations for gene
inactivation in gastric carcinogenesis. Although a number of gastric cancer-associated …

Background: Gastric cancer (GC) is one of the most common malignancies, with a low 5-
year survival rate. However, if diagnosed at an early stage, it can be cured by endoscopic …

BACKGROUND: Promoter methylation is an alternative mechanism of gene silencing in
human tumorigenesis. Although a number of methylated genes have been found in gastric …

Despite a decline in the overall incidence of gastric cancer (GC), the disease remains the
second most common cause of cancer-related death worldwide and is thus a significant …

Background Gastric cancer (GC) is a leading cause of cancer death and an important barrier
to increasing life expectancy in China. Early detection of GC can significantly reduce its …

Background Tumor samples are unavoidably contaminated with coexisting normal cells.
Here, we aimed to establish a DNA methylation marker to estimate the fraction of gastric …

Introduction The early diagnosis and detection could greatly improve the clinical outcome of
gastric cancer (GC) patients. However, the non-invasive biomarkers for GC detection remain …